Keita Nakane

25PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)PodiatryPacific Peoples theory of change models for health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 15, 2026
Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med. 2021, 10, 5325.

|Aug 28, 2026
Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

|Jun 12, 2026
Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

|May 20, 2026
Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

|Oct 01, 2025
Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly-Metastatic Prostate Cancer.

Makoto Kawase, Kota Kawase, Yuki Tobisawa

|May 28, 2025
Impact of Estimated Glomerular Filtration Rate and Serum C-Reactive Protein Level to Overall Survival After Second-Line Targeted Therapy Following Immuno-Oncology Combination Therapy for Advanced Renal Cell Carcinoma.

Keita Nakane, Hiromitsu Watanabe, Taku Naiki

Pageof 5

Frequent Collaborators

18 joint publications

Takuya Koie

12 joint publications

Koji Iinuma

9 joint publications

Makoto Kawase

7 joint publications

Daiki Kato